Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;113(4):501-509.
doi: 10.1111/ejh.14259. Epub 2024 Jun 30.

The German sickle cell disease registry reveals a surprising risk of acute splenic sequestration and an increased transfusion requirement in patients with compound heterozygous sickle cell disease HbS/β-thalassaemia and no or low HbA expression

Pierre Allard  1 , Laura Tagliaferri  1   2 , Vivienn Weru  3 , Holger Cario  2   4 , Stephan Lobitz  2   5 , Regine Grosse  2 , Matthias Bleeke  2   6 , Lena Oevermann  2   7 , Dani Hakimeh  2   7 , Andrea Jarisch  2   8 , Annette Kopp-Schneider  3 , Andreas E Kulozik  1   2 , Joachim B Kunz  1   2 ; German Sickle Cell Disease Study Group; Lisa Lassay
Collaborators, Affiliations

The German sickle cell disease registry reveals a surprising risk of acute splenic sequestration and an increased transfusion requirement in patients with compound heterozygous sickle cell disease HbS/β-thalassaemia and no or low HbA expression

Pierre Allard et al. Eur J Haematol. 2024 Oct.

Abstract

Patients with sickle cell disease (SCD) in Germany exhibit a substantial genetic diversity in the β-globin genotype. Data collected by the national German SCD registry reflect this diversity and allowed us to analyze the phenotypes associated with different SCD genotypes. Our study focused on 90 patients with HbS/β-thalassaemia (HbS/β-thal) and compared these to patients with HbSS and HbSC. Patients with HbS/β-thal were classified into three groups: HbS/β0-thal (no HbA), HbS/β+-thal (HbA < 14%), and HbS/β++-thal (HbA≥14%). In comparison to HbSS, patients with HbS/β++-thal had higher Hb-levels, lower hemolytic activity and rarely required red blood cell transfusions. HbS/β0-thal and HbS/β+-thal closely resembled each other and are jointly referred to as HbS/β0/+-thal. Compared to HbSS, patients with HbS/β0/+-thal experienced a similar frequency of vasoocclusive crises and degree of hemolysis. However, the frequency of red blood cell transfusions (0.6 vs. 0.39/year, p = .0049) and splenic sequestration crises (42.4 vs. 15.5% of patients, p = 3.799e-05) was higher in HbS/β0/+-thal than in HbSS, but close to zero in HbS/β++-thal. In conclusion, the level of HbA expression determines the phenotype of HbS/β+-thal. HbS/β-thal expressing no or little HbA is hematologically similar to HbSS, but causes a previously unknown high risk of splenic sequestration.

Keywords: anemia; sickle cell; thalassemia.

PubMed Disclaimer

References

REFERENCES

    1. Kunz JB, Cario H, Grosse R, Jarisch A, Lobitz S, Kulozik AE. The epidemiology of sickle cell disease in Germany following recent large‐scale immigration. Pediatr. Blood Cancer. 2017;64(7):1‐10.
    1. Kunz JB, Schlotmann A, Daubenbuchel A, et al. Benefits of a disease management program for sickle cell disease in Germany 2011–2019: the increased use of hydroxyurea correlates with a reduced frequency of acute chest syndrome. J. Clin. Med. 2021;10(19):4543. doi:10.3390/jcm10194543
    1. Kunz JB, Lobitz S, Grosse R, et al. Sickle cell disease in Germany: results from a national registry. Pediatr. Blood Cancer. 2020;67(4):e28130.
    1. Allard P, Alhaj N, Lobitz S, et al. Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea. Haematologica. 2022;107(7):1577‐1588.
    1. Yawn BP, Buchanan GR, Afenyi‐Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members. JAMA. 2014;312(10):1033‐1048.

MeSH terms

LinkOut - more resources